Introduction {#sec0001}
============

Since December 2019, when the first case of Coronavirus Disease 2019 (COVID-19), caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) was identified in Wuhan (China), an increasing number of people have been diagnosed with the disease (<https://covid19.who.int/>). This prompted World Health Organization to declare the pandemic on March 11^th^ and several countries have established quarantine policies.

In COVID-19 hospitalized patients, acute stroke has been observed in 1% to 2.5% of cases with high in-hospital mortality rate.[@bib0001], [@bib0002], [@bib0003] Although COVID-19 pandemic has produced an enormous collateral damage over stroke systems of care leading to a drop of mild strokes admissions and late arrival of severe strokes, only incidental cases of large vessel occlusion (LVO) in young adults infected by SARS-CoV-2 have been reported without a clear causative relationship.[@bib0004] The presence of antiphospholipid antibodies[@bib0005] and the endothelial cell dysfunction[@bib0006] have been proposed as possible mechanisms that could induce a stroke in COVID-19 patients.

An increased rate of thrombotic events,[@bib0007] ^,^ [@bib0008] mainly venous thromboembolism and acute pulmonary embolism have been associated with COVID-19. The infection may cause an hypercoagulable state supported by the presence of disseminated intravascular coagulation in most deaths[@bib0009] and the results of autopsy reports.[@bib0010]

The presence of SARS-CoV-2 infection has been associated with worse functional outcome and higher mortality among patients with acute stroke;[@bib0011] in parallel, history of stroke has also been associated with more severe clinical symptoms and poorer outcomes in patients with COVID-19.[@bib0012]

Our aim is to uncover the rate of acute stroke in COVID-19 patients admitted in a high-volume center and identify those cases in which a possible causative relationship could exist.

Methods {#sec0002}
=======

Ethics approval was obtained from Hospital Universitari Vall d\'Hebron institutional review board (PR(AG)237/2020). No specific investigational measures were applied for the purpose of this study. Written informed consent was waived due the retrospective nature of the study. The data that support the findings of this study are available from the corresponding author on reasonable request.

Starting March 2^nd^ 2020, all patients admitted to our institution were clinically screened for COVID-19 and a respiratory sample was obtained depending on clinical suspicion. We performed a single-center retrospective analysis of a prospective mandatory database that includes all stroke patients diagnosed in our institution. We studied all patients with confirmed COVID-19 and stroke diagnoses from March 2^nd^ to April 30^th^. Demographic, clinical, and imaging data were prospectively collected. Among stroke data, National Institutes of Health Stroke Scale (NIHSS) score and prestroke modified Rankin Scale (mRS) score were assigned by the stroke neurologist on call.

Final diagnosis and Trial of ORG 10172 in Acute Stroke Treatment (TOAST) classification was determined after full diagnostic work-up according to ESO guidelines unless impossible due to death. The diagnostic work-up included a 12-lead ECG on admission, parenchymal and vascular neuroimaging (computed tomography or magnetic resonance imaging), continuous ECG monitoring for at least 72 hours and transthoracic or transesophageal echocardiogram. We defined a stroke as cryptogenic when after full work-up there was no sufficient cause.

Recorded imaging variables included Alberta Stroke Program Early CT Score (ASPECTS), presence of a LVO (extracranial internal carotid artery, intracranial internal carotid artery, M1 and M2 segments of middle cerebral artery, basilar artery, A1 segment of anterior cerebral artery, P1 segment of posterior cerebral artery) and presence of an intracranial hemorrhage (ICH); these variables were determined by the local neuroradiologist. Workflow times including onset, arrival, imaging, and groin puncture were also recorded.

Patients received intravenous-tPA (tissue-type plasminogen activator) and endovascular treatment when indicated independently of COVID-19 diagnosis according to current guidelines. Endovascular procedures were performed by experienced interventionalists using commercially available stent retrievers and aspiration catheters. At the end of the procedure, recanalization was assessed according to modified Thrombolysis in Cerebral Infarction (TICI);[@bib0013] successful recanalization was considered if the score was 2b or 3. We explored baseline and prognostic differences between patients who underwent EVT in the same period in function of SARS-CoV-2 status.

SARS-CoV-2 infection was considered when confirmed by real-time reverse transcription polymerase chain reaction (RT-PCR) assay on respiratory samples obtained in the two weeks prior to stroke onset or during hospital admission. COVID-19 symptoms, clinical signs, laboratory findings, chest imaging (radiography or CT scan) findings were collected by trained physicians. Severe COVID-19 was defined as[@bib0001] patients requiring ICU admission,[@bib0002] acute respiratory distress syndrome criteria defined as low oxygen saturation by pulse-oximetry correlated to the inspired fraction of oxygen (SpO2/FiO2 ratio \< 315)[@bib0003] or death due to acute respiratory failure.

Statistical analysis {#sec0003}
--------------------

We obtained descriptive and frequency statistical analyses using SPSS V.23.0 software. Shapiro-Wilk test was used to assure normality of continuous variables. Categorical variables were presented as absolute values and percentages and continuous variables as median (interquartile range (IQR)) or means (± standard deviation (SD)) as indicated. Statistical significance for intergroup differences was assessed by Pearson χ2 test or Fisher exact test for categorical variables and by Mann-Whitney U test or Student t test as indicated for continuous variables.

Multivariable logistic regression analyses were used to determine factors that could be considered as independent predictors of good functional outcomes. The analyses were adjusted using the variables that previously were shown statistical trends or differences between groups. The OR along with its 95% confidence interval based on logistic regression was reported. A p-value \<0.05 was considered statistically significant.

Results {#sec0004}
=======

From March 2^nd^ to April 30^th^, 2050 patients were admitted to our center with RT-PCR confirmed SARS-CoV-2 infection; of them 21 (1.02%) presented an acute ischemic stroke 21 and 4 (0.2%) suffered an ICH. Demographic and clinical data are shown in [Table 1](#tbl0001){ref-type="table"} .Table 1Demographic and clinical data of patients with stroke possibly related and unrelated to COVID-19. COVID-19 indicates Coronavirus Disease 19; SD, standard deviation; IQR, interquartile range; ICU, intensive care unit; NIHSS, National Institutes of Health Stroke Scale; iv-tPA, intravenous tissue-type plasminogen activator; EVT, endovascular treatment.Table 1All stroke (N = 25)Stroke unknown/infrequent etiology (N = 9)Stroke known etiology (N = 16)p valueAge (mean, SD)66.5 (15.2)56.6 (17.3)72.1 (10.7)0.01Gender (male)14 (56.0%)4 (44.4%)10 (62.5%)0.38prestroke mRS (median, IQR)1 (0-2)0 (0-1)1 (0-2)0.22**Vascular risk factors**Hypertension14 (56.0%)5 (55.6%)9 (56.3%)0.97Diabetes mellitus9 (36.0%)3 (33.3%)6 (37.5%)0.83Hyperlipidemia11 (44.0%)3 (33.3%)8 (50.0%)0.42Current smoker8 (32.0%)3 (33.3%)5 (31.3%)0.92Atrial fibrillation4 (16.0%)04 (25.0%)0.1Obesity6 (24.0%)3 (33.3%)3 (18.8%)0.41**COVID-19 infection**Prestroke symptoms17 (68.0%)9 (100%)8 (50%)0.02Days of evolution (mean, SD)12 (7.5)14.9 (8.4)9.4 (5.9)0.14ICU admission8 (32.0%)6 (66.7%)2 (12.5%)0.02Severe infection14 (56.0%)9 (100%)6 (37.5%)0.01**Stroke**NIHSS (median, IQR)16[@bib0008], [@bib0009], [@bib0010], [@bib0011], [@bib0012], [@bib0013], [@bib0014], [@bib0015], [@bib0016], [@bib0017], [@bib0018], [@bib0019], [@bib0020], [@bib0021]10[@bib0006], [@bib0007], [@bib0008], [@bib0009], [@bib0010], [@bib0011], [@bib0012], [@bib0013], [@bib0014], [@bib0015], [@bib0016], [@bib0017], [@bib0018], [@bib0019], [@bib0020], [@bib0021], [@bib0022], [@bib0023], [@bib0024], [@bib0025], [@bib0026]16[@bib0009], [@bib0010], [@bib0011], [@bib0012], [@bib0013], [@bib0014], [@bib0015], [@bib0016], [@bib0017], [@bib0018], [@bib0019], [@bib0020]0.82Unknown onset14 (56.0%)6 (66.7%)8 (50.0%)0.52Ischemic stroke21 (84.0%)9 (100%)12 (75.0%)0.10Intracranial hemorrhage4 (16.0%)04 (25.0%)0.10iv-tPA5 (20.0%)2 (22.2%)3 (18.8%)0.84EVT10 (40.0%)4 (44.4%)6 (37.5%)0.61**Short-term outcome**24h NIHSS (median, IQR)12[@bib0004], [@bib0005], [@bib0006], [@bib0007], [@bib0008], [@bib0009], [@bib0010], [@bib0011], [@bib0012], [@bib0013], [@bib0014], [@bib0015], [@bib0016], [@bib0017], [@bib0018], [@bib0019]6[@bib0001], [@bib0002], [@bib0003], [@bib0004], [@bib0005], [@bib0006], [@bib0007], [@bib0008], [@bib0009], [@bib0010], [@bib0011], [@bib0012], [@bib0013], [@bib0014], [@bib0015]17 (5.5-20)0.10In-hospital mortality10 (40.0%)3 (33.3%)7 (43.8%)0.50

Seventeen (68.0%) patients presented COVID-19 symptoms before stroke onset with a mean duration of 12 (SD 7.5) days; 6 patients without symptoms were diagnosed at admission by screening test, the 2 others presented symptoms in the first 48 hours after hospital admission. Severe COVID-19 infection was diagnosed in 14 (56.0%) patients, 8 of them were admitted to the ICU.

After the diagnostic work-up, in 12 (60.0%) ischemic stroke patients (4 large-artery atherosclerosis, 8 cardioembolism (4 atrial fibrillation, 1 atrial flutter, 3 severe depressed left ventricular ejection fraction) and all ICH patients (2 anticoagulated patients, 1 hypertensive ICH, 1 hemophilia) an etiology non-related with COVID-19 was identified. Among the remaining ischemic stroke patients, 3 died before completing etiologic work-up and in 6 (0.3% of all COVID-19 patients admitted in our hospital) the stroke cause was related to infrequent etiologies that could be related to or at less linked with SARS-CoV-2 infection. Three of them presented a posterior reversible encephalopathy syndrome (PRES);[@bib0014] one presented a paradoxical embolism and in two no cause was identified after completing diagnostic work-up. Patients' data are shown in [Table 2](#tbl0002){ref-type="table"} . Severe COVID-19 condition (100% vs. 37.5%, p = 0.01), ICU admission (66.7% vs. 12.5%, p = 0.02) and the presence of COVID-19 symptoms before stroke (100% vs. 50%, p = 0.02) were more frequent among patients in which stroke wasn\'t related to a usual stroke etiology. A logistic regression model adjusting for all these variables and age showed that severe COVID-19 condition was an independent predictor of stroke without a usual etiology (OR 13.3, 95% CI, 1.3-134.6; p 0.02).Table 2Characteristics of six patients with stroke possibly related with SARS-CoV-2 infection. COVID-19 indicates Coronavirus Disease 19; ICU, intensive care unit; NIHSS, National Institutes of Health Stroke Scale; MCA, middle cerebral artery; CT, computed tomography; MRI, magnetic resonance imaging; PRES, posterior reversible encephalopathy syndrome. Reference range are as follows: D-dimer 0-243ng/ml; Ferritin 25-400ng/ml; Lymphocytes 1200-3500 per mm³.Table 2Patient 1Patient 2Patient 3Patient 4Patient 5**Patient 6**GenderMaleFemaleFemaleFemaleFemaleFemaleAge (decade)60s40s40s50s30s40sRisk factors for strokeHypertensionPuerperiumNoneHypertension, Diabetes mellitus, obesity, chronic kidney diseaseNoneNone**COVID-19 features**Severe diseaseYesYesYesYesYesYesMechanical ventilationYesYesYesYesYesYesICU admissionYesYesYesYesYesYesTreatmentHydroxychloroquine, Ritonavir/lopinavir, Glucocorticoids, TocilizumabAzitromicine, Hydroxychloroquine, Ritonavir/lopinavir, TocilizumabAzitromicine, Hydroxychloroquine, Ritonavir/lopinavir, CeftriaxoneAzitromicine, Hydroxychloroquine, Ceftriaxone, Darunavir/cobicistat,Azitromicine, Hydroxychloroquine, Ritonavir/lopinavir, Tocilizumab, CeftriaxoneAzitromicine, Hydroxychloroquine, Ritonavir/lopinavir, TocilizumabD-dimer (ng/ml)6800734183317902464430Ferritin (ng/ml)105416423623536051020Lymphocytes per mm³122414001900180016001600Other relevant medical complicationsDeep vein thrombosisNoneCatheter-associated subclavian vein thrombosisSeptic shock, pneumothoraxNoneStaphylococcus aureus bacteriemiaDays from symptom onset to acute stroke35 days14 days30 days38 days19 days25 days**Stroke features**NIHSS311822810CT/MRI findingsBilateral cortical infarctsTiny protuberance infarctM1-segment of MCA occlusionPRESPRESPRES, vasoconstrictionProbable causeUnknownUnknownParadoxical embolismPRESPRESPRES

Overall, in-hospital mortality rate was 36% (9/25): 5 (50%) LVO patients, 2 (18.2%) non-LVO ischemic stroke patients and 2 (50%) ICH patients died. Of them, 3 deaths were directly related with stroke severity (2 ICH and 1 LVO), 5 deaths were directly related with SARS-CoV-2 infection and 1 presented 2 possible causes (basilar artery occlusion successfully treated and severe hypoxemia).

Among patients with ischemic stroke, 5 (23.8%) received iv-tPA without any hemorrhagic transformation and 10 (47.6%) underwent EVT with a median time from last seen well to groin puncture of 222.5 (IQR 142.5-492.5) minutes. Among patients who underwent EVT, 8 presented intracranial LVO and two underwent acute extracranial stenting due to chronic carotid occlusion without intracranial LVO that became symptomatic in the context of severe hypoxemia. The median door-to-groin time was 118 minutes (IQR 45-134) and in 5 of the 8 patients (62.5%) with intracranial occlusion a successful recanalization was achieved. We did not find differences in baseline characteristics with patients who underwent EVT during the same period in our center ([Table 3](#tbl0003){ref-type="table"} ) except a higher rate of unknown onset stroke and a longer last-time-seen-well to groin time among patients without COVID-19.Table 3Demographic and clinical data of patients who underwent EVT in function of COVID-19 status. COVID-19 indicates Coronavirus Disease 19; EVT, endovascular treatment; SD, standard deviation; IQR, interquartile range; ICU, intensive care unit; NIHSS, National Institutes of Health Stroke Scale; iv-tPA, intravenous tissue-type plasminogen activator; MCA, middle cerebral artery; TICA, terminal internal carotid artery; BA, basilar artery; TICI, Thrombolysis in Cerebral Infarction; ICH, intracranial hemorrhage; LTSW, last time seen well.Table 3COVID-EVT (N = 10)NO COVID-EVT (N = 19)p valueAge (mean, SD)70.8 (14.8)71.0 (15.9)0.97Gender (male)6 (60.0%)11 (57.9%)0.91**Vascular risk factors**Hypertension6 (60.0%)10 (52.6%)0.71Diabetes mellitus4 (40.0%)4 (21.0%)0.28Hyperlipidemia5 (50.0%)7 (36.8%)0.49Current smoker3 (30.0%)6 (31.6%)0.93Atrial fibrillation2 (20.0%)4 (21.0%)0.94**COVID-19 infection**Prestroke symptoms9 (90.0%)\--Days of evolution (mean, SD)11.7 (7.3%)\--ICU admission2 (20.0%)\--Severe infection7 (70.0%)\--**Stroke**NIHSS (median, IQR)18[@bib0011], [@bib0012], [@bib0013], [@bib0014], [@bib0015], [@bib0016], [@bib0017], [@bib0018], [@bib0019], [@bib0020], [@bib0021], [@bib0022], [@bib0023], [@bib0024], [@bib0025]17[@bib0009], [@bib0010], [@bib0011], [@bib0012], [@bib0013], [@bib0014], [@bib0015], [@bib0016], [@bib0017], [@bib0018], [@bib0019], [@bib0020], [@bib0021]0.27[Site of occlusion]{.ul}0.22MCA-M12 (20.0%)9 (47.4%)MCA-M24 (40.0%)5 (26.3%)TICA1 (10.0%)3 (15.8%)Extracranial ICA2 (20.0%)0BA1 (10.0%)2 (10.5%)Unknown onset2 (20.0%)11 (57.9%)0.05iv-tPA1 (10.0%)5 (26.3%)0.27**Endovascular procedure**TICI 2b-35 (62.5%)\*16 (84.2%)0.30LTSW to groin time (minutes) (median, IQR)222.5 (142.5-492.5)570 (256-860)0.03Door to groin time (minutes) (median, IQR)118 (45.5-134.5)75 (46-93.5)0.15**Short-term outcome**24h NIHSS (median, IQR)18[@bib0007]^-42^15[@bib0005], [@bib0006], [@bib0007], [@bib0008], [@bib0009], [@bib0010], [@bib0011], [@bib0012], [@bib0013], [@bib0014], [@bib0015], [@bib0016], [@bib0017], [@bib0018], [@bib0019], [@bib0020], [@bib0021]0.06Symptomatic ICH00-In-hospital mortality5 (50.0%)3 (15.8%)0.03

In patients who underwent EVT during the study period, COVID-19 was an independent predictor of in-hospital mortality (50% versus 15%; Odds Ratio, 6.67; 95% CI, 1.1-40.4; p 0.04) and presented a trend to a higher median of NIHSS score at 24 hours (18 (IQR 7-42) vs. 15;[@bib0005] ^--^ [@bib0021] p = 0.06).

Discussion {#sec0005}
==========

Our study shows that the frequency of acute stroke in patients with COVID-19 requiring hospital admission is low (1%) and in most cases a usual cause of stroke was identified. Moreover, all patients with an acute stroke without a usual etiology presented a severe infection requiring mechanical ventilation.

Severe respiratory disease has been previously linked to neurological symptoms and in particular to stroke.[@bib0015] Neurological disorders were also described in patients affected by other coronavirus as Middle East Respiratory Syndrome or SARS-CoV.[@bib0016] Cerebral ischemia associated with severe infections is not new to COVID-19; the association of sepsis with intravascular coagulopathy and platelet activation is well known and has been described as a potential cause of stroke.[@bib0017] Recent bacterial and viral infections have been repeatedly reported as a risk factor for ischemic stroke.[@bib0018] ^--^ [@bib0021] On the other hand, influenza vaccination, by reducing the infection rate, has been associated with a reduction in risk of stroke and myocardial infarction.[@bib0022] ^,^ [@bib0023] In all cases, stroke is an uncommon complication of the infectious disease and according to our observations SARS-CoV2 seems to follow the same pattern. Therefore, among COVID-19 patients, and mainly in the absence of severe symptoms, the stroke cause should not be directly attributed to SARS-CoV-2, and an exhaustive diagnostic work-up must be completed.

In the majority of patients in which stroke etiology was possibly related to SARS-CoV-2 infection elevated D-Dimer and ferritin levels were found. High levels of D-Dimer and inflammatory markers have been previously related to COVID-19 severity.[@bib0024] These laboratory findings, together with the fact that 3 patients presented PRES and 2 deep vein thrombosis, suggest an inflammatory and coagulopathy state possibly associated to the ischemic brain injury.[@bib0025]

The infrequent but possible causal relation of SARS-CoV-2 and ischemic stroke observed in our study could not be confirmed for ICH. During the study period we did not observe an increase in ICH admissions and in all cases a usual ICH cause was identified. Moreover none of the patients receiving reperfusion therapies experienced a symptomatic hemorrhagic transformation, suggesting that COVID-19 patients should not be excluded from these treatments for safety reasons.

It is not possible to determine if COVID-19 could act as a trigger in those patients with an identified usual stroke cause. Severe COVID-19 was less frequent among these stroke patients (37.5%), this rate is not higher than in previously published series of COVID patients admitted to a hospital.[@bib0026] ^,^ [@bib0027] In two of our cases, hypoxemia was considered the triggering stroke factor in patients with chronic extracranial carotid occlusion. Therefore COVID-19 patients with pre-existing vascular risk factors should undergo regular neurological exams.

In our study, the concomitant presence of LVO and SARS-CoV-2 infection was associated with a high rate of in-hospital mortality (50%) despite of mechanical thrombectomy. Of the 5 patients who died, 4 (80%) presented a severe infection ([Figure 1](#fig0001){ref-type="fig"} ) and the remaining was an elder patient in whom mechanical thrombectomy was not successful (TICI 0 at the end of EVT). A logistic regression model applied all patients undergoing EVT during the study period confirmed SARS-CoV2 infection as an independent predictor of mortality.Fig. 1Acute ischemic stroke due to a large vessel occlusion in a patient with a severe COVID-19. A and B, severe pulmonary injury showed on CT angio and radiography. C, CT perfusion maps. D, M2-middle cerebral artery occlusion.Fig. 1

This study has some limitations and strengths. The main limitations are:[@bib0001] it is a single center study;[@bib0002] even despite stroke neurologists were involved in COVID-19 teams in different settings (Emergency department, hospitalization and ICU) cases of minor stroke have not been detected, mainly in critically ill patients in which neurological exam may be challenging;[@bib0003] some patients did not have a complete diagnostic work-up and[@bib0004] most asymptomatic patients were not tested for COVID-19 by RT-PCR. On the other hand, all COVID-19 patients admitted during the study period were accounted, the etiological diagnostic work-up was always guided by a stroke neurologist and all data were obtained from a mandatory prospective registry.

In conclusion, less than 2% of COVID-19 patients admitted to our hospital presented an associated stroke. In most cases a usual stroke cause was identified. In patients without any other potential cause, stroke was an uncommon complication only seen in patients with a severe pulmonary injury. In stroke patients with LVO, the presence of COVID-19 was a strong predictor of in-hospital mortality.
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